Pediatric studies of promising cancer drugs can begin before an optimized dosage is identified for adults, but there should be a prospect for clinical benefit in pediatric patients and, ideally, an age-appropriate formulation, the US Food and Drug Administration and its external experts said at a recent advisory committee meeting.
While FDA officials said they recognize that premarketing randomized trials for dosage optimization may not always be possible, some panelists...